Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as… | Phase 2 / Phase 3 | terminated | Oct 6, 2016 | SWOG Cancer Research Network | Drug company decided to terminate all sponsored clinical studies involving rilotumumab. | Sponsor / business decision |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent… | Phase 1 | withdrawn | Jan 8, 2009 | University of Maryland, Baltimore | There was no patient accrual nor study activity due to inability to fund PFTs. | Enrollment / accrual |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable -… | Phase 2 | terminated | Jul 2, 2018 | Montefiore Medical Center | Poor accrual | Enrollment / accrual |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | Phase 1 | terminated | Apr 26, 2010 | University of Maryland, Baltimore | Toxicity was not felt to be acceptable for further development. | Safety / toxicity |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic… | Phase 1 | terminated | Jul 9, 2018 | Regeneron Pharmaceuticals | Program reprioritization | Other (stated, no rule matched) |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients… | Phase 1 | terminated | Jun 30, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03763851 | Cannabis Oil and Radiation Therapy for the Management of Pain | Phase 2 | terminated | Dec 4, 2018 | Tetra Bio-Pharma | due to mycotoxin potential contamination of one lot of study drug | Other (stated, no rule matched) |
| NCT01717482 | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | Phase 2 | terminated | Oct 30, 2012 | Mayo Clinic | Poor accrual and funding ended | Enrollment / accrual |
| NCT03302221 | Regional Haemodynamic Changes in Radial Artery Assessment With Continuous Pulsed-wave… | Phase 4 | withdrawn | Oct 5, 2017 | China Medical University, China | No participants enrolled | Enrollment / accrual |
| NCT03198117 | Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small… | N/A | terminated | Jun 23, 2017 | Qidong Gaitianli Medicines Co., Ltd | Difficulty in patient recruitment | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT03460678 | Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of… | Phase 4 | terminated | Mar 9, 2018 | Hikma Pharmaceuticals LLC | Difficulty recruiting | Enrollment / accrual |
| NCT03678090 | The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter… | Phase 2 | withdrawn | Sep 19, 2018 | Yale University | Local IRB recommended IND exemption from FDA, study timeline not able to be met. | Other (stated, no rule matched) |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and… | Phase 1 | terminated | Jun 14, 2010 | National Cancer Institute (NCI) | Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same… | Enrollment / accrual |
| NCT03524248 | Development of Real-time Image-guided Radiotherapy | N/A | terminated | May 14, 2018 | Fox Chase Cancer Center | Camera for study is being repaired | Other (stated, no rule matched) |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab,…(iTRAP) | Phase 1 | withdrawn | Apr 13, 2018 | Queen Mary University of London | Funder and IMP manufacturer withdrew support | Drug supply |
| NCT01557881 | Positron Emission Tomography/Magnetic Resonance Imaging in Patients | N/A | terminated | Mar 20, 2012 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared… | Phase 1 | terminated | Jun 11, 2015 | Novartis Pharmaceuticals | Major challenge for enrollment of participants. | Enrollment / accrual |
| NCT03589456 | Establishment of a PDT Patient Registry | — | terminated | Jul 17, 2018 | Concordia Laboratories Inc. | Study was closed to accrual on January 15, 2020. | Enrollment / accrual |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For… | Phase 2 | terminated | Jun 11, 2015 | howard safran | Lack of accrual | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Phase 2 | terminated | Apr 17, 2014 | Heat Biologics | Sponsor Decision; strategic - based on changing treatment landscape | Sponsor / business decision |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell… | Phase 1 | withdrawn | Mar 28, 2013 | Acrotech Biopharma Inc. | not stated | Not stated |
| NCT03110939 | Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung… | N/A | withdrawn | Apr 12, 2017 | Henan Cancer Hospital | The principal investigator Dr.YinLi is working in other Hospital | Investigator |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung… | Early Phase 1 | terminated | Oct 16, 2012 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | — | terminated | Apr 10, 2012 | Addario Lung Cancer Medical Institute | interim assessment by sponsor | Other (stated, no rule matched) |
| NCT03872440 | PDX Models From EGFR Mutant Tumors | — | withdrawn | Mar 13, 2019 | Addario Lung Cancer Medical Institute | Did not meet the expected enrollment rate. | Enrollment / accrual |
| NCT02285855 | Metformin in Non Small Cell Lung Cancer (NSCLC) | Phase 2 | terminated | Nov 7, 2014 | M.D. Anderson Cancer Center | Poor Accrual | Enrollment / accrual |
| NCT01952860 | Hatha Yoga in Lung Cancer Couples | N/A | terminated | Sep 30, 2013 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | Phase 1 | terminated | Jul 20, 2010 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | Phase 2 | terminated | Jun 20, 2012 | National Cancer Institute (NCI) | Study closed due to low accrual. | Enrollment / accrual |
| NCT01918761 | Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung… | Phase 1 | terminated | Aug 8, 2013 | Central European Cooperative Oncology Group | poor accrual | Enrollment / accrual |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to… | Phase 1 | terminated | Dec 18, 2013 | Eli Lilly and Company | This trial was terminated early based on the lack of sufficient clinical efficacy observed. | Efficacy / futility |
| NCT03564054 | Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With… | N/A | terminated | Jun 20, 2018 | University of Florida | slow accrual | Enrollment / accrual |
| NCT01086696 | A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors… | Early Phase 1 | terminated | Mar 15, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | Early Phase 1 | terminated | Aug 10, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | Sep 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00585117 | Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients | N/A | terminated | Jan 3, 2008 | University of Wisconsin, Madison | change in imaging priorities | Other (stated, no rule matched) |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | Phase 2 / Phase 3 | terminated | Jul 18, 2013 | University of Wisconsin, Madison | Clinicians were not offering the study to eligible potential subjects. | Other (stated, no rule matched) |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or… | Phase 1 | terminated | Oct 29, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02501707 | Echocardiography for RILI Prediction | — | terminated | Jul 17, 2015 | Maastricht Radiation Oncology | The study is prematurely terminated due to bad inclusion and the fact that examinations are already… | Other (stated, no rule matched) |
| NCT01258868 | Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing… | Phase 1 | terminated | Dec 13, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03232892 | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell… | Phase 2 | terminated | Jul 28, 2017 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT00923273 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure - investigator left the National Institutes of Health. | Investigator |
| NCT02770014 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | Phase 2 | terminated | May 12, 2016 | Dana-Farber Cancer Institute | Terminated due to Osimertinib approval | Other (stated, no rule matched) |
| NCT03529084 | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally… | Phase 3 | withdrawn | May 18, 2018 | Novartis Pharmaceuticals | Decision by Sponsor not to continue with the trial. | Other (stated, no rule matched) |
| NCT01993901 | The Influence of CSRT-led Telephone Follow-up on ESAS Scores in Patients Who Have Been… | N/A | withdrawn | Nov 25, 2013 | Sunnybrook Health Sciences Centre | Study never officially opened | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Mar 19, 2020source: clinicaltrials